Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

NIAID closes ACTIV-3 substudies of BRII-196, BRII-198 and VIR-7831

March 5, 2021

Apellis ends development of APL-9 for severe COVID-19

March 5, 2021

COVID-eVax vaccine enters phase I/II study

March 4, 2021

Arbutus Biopharma identifies HBsAg secretion inhibitors

March 4, 2021

MediciNova discontinues development of vaccine for COVID-19

March 4, 2021

Cerecor reports final phase II efficacy data on CERC-002 in hospitalized COVID-19 patients

March 3, 2021

Tocilizumab does not significantly improve clinical status in severe COVID-19 pneumonia

March 3, 2021

Positive interim analysis data from ongoing FURI and CARES phase III trials of ibrexafungerp

March 3, 2021

Takeda initiates phase I/II study in Japan with NVX-CoV2373

March 1, 2021

New SARS-CoV-2 main protease inhibitors display antiviral activity in vivo

March 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...